ClinicalTrials.gg
Active, not recruitingNCT05104866Updated Aug 24, 2026Results posted

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

A Phase 3 interventional study of Dato-DXd and Capecitabine in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 167 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Enrollment
4th of 14
732 · median 300
Started
2021
the only one that year
Phase 3
6 of 14
2 open now
Primary completion
2024-07
later than 0 of 13 live
Registered
3rd of 14
by date
Lead sponsor
7 of 14
AstraZeneca

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 3, reaches primary completion later than 0 of the 13 other live ones, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

Read the detailed description

The primary objective of this study will assess the safety and efficacy of datopotamab deruxtecan (Dato-DXd) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

The study will be stratified based on number of previous lines of chemotherapy (1 vs. 2), prior use of CDK4/6 inhibitors (Yes vs. no) and geographic region of participant (US/Canada/Europe vs. rest of world).

This study aims to see if datopotamab deruxtecan allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast Cancer
  • HR positive
  • Hormone Receptor positive
  • ER positive
  • PR positive
  • HER2 negative
  • Inoperable
  • Metastatic
  • Datopotamab Deruxtecan
  • Dato-DXd
  • DS1062
  • DS1062a
  • Capecitabine
  • Eribulin
  • Gemcitabine
  • Vinorelbine
  • TROP2
  • Antibody Drug Conjugate
  • ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age • Participant must be ≥ 18 years at the time of screening.

Type of Participant and Disease Characteristics

  • Inoperable or HR+, -negative breast cancer
  • Progressed on and not suitable for endocrine therapy per investigator assessment and treated with 1 to 2 in the inoperable/metastatic setting. Participant must have documented progression on their most recent line of chemotherapy.
  • Eligible for one of the chemotherapy options listed as ICC (eribulin, capecitabine, vinorelbine, gemcitabine), per investigator assessment.
  • PS of 0 or 1, with no deterioration over the previous 2 weeks prior to day of first dosing.
  • At least 1 not previously irradiated that qualifies as a 1.1. Note: Participants with bone-only metastases are not permitted.
  • Participants with a history of previously treated neoplastic spinal cord compression, or clinically inactive , who require no treatment with or anticonvulsants, may be included in the study, if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and study enrolment.
  • Adequate organ and bone marrow function within 7 days before day of first dosing as follows:

    • : ≥ 9.0 g/L.
    • : 1500/mm3.
    • count: 100000/mm3. • Total : ≤ 1.5 × if no liver metastases; or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.
    • and AST: ≤ 3 × ULN for AST/ALT; however, if elevation is due to liver metastases, ≤ 5.0 × ULN is allowed.
    • Calculated : ≥ 30 mL/min as calculated using the Cockcroft-Gault equation (using actual body weight).
  • ≥ 50% by either an echocardiogram or MUGA within 28 days of first dosing.
  • Has had an adequate treatment before Cycle 1 Day 1, defined as:

    • Major surgery: ≥ 3 weeks.
    • Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
    • Anticancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
    • Antibody-based anticancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
    • Immunotherapy (non-antibody-based therapy): ≥ 2 weeks or 5 times the terminal elimination T½ of the agent, whichever is longer.
    • Chloroquine/hydroxychloroquine: > 14 days.
  • Have available a FFPE tumor sample (block preferred, or a minimum of 20 freshly cut slides), at the time of screening. Note: Sample collection in China will comply with local regulatory approval.
  • Minimum of 12 weeks at screening.

Sex

  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; (oral estrogens are not permitted).

Reproduction

  • Negative pregnancy test (serum) for women of
  • Female participants must be for at least 1 year, surgically sterile, or using one highly effective form of birth control. Female participants must refrain from egg cell donation and breastfeeding while on study and for at least 7 months after the last dose of study intervention. Non-sterilized male partners of a woman of childbearing potential must use a male condom plus spermicide throughout this period.
  • Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using a highly effective method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 4 months after the last dose of study intervention) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female partners of male participants are allowed to use HRT for contraception.

  • Capable of giving signed informed consent.
  • Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.

Exclusion criteria

Exclusion Criteria

Medical Conditions

  • Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
  • History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy, adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated.
  • Persistent toxicities caused by previous anticancer therapy (excluding alopecia), not yet improved to Version 5.0 Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to > Grade 2 for at least 3 months prior to first dosing and managed with SoC treatment) which the investigator deems related to previous anticancer therapy.
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections.
  • Known active or uncontrolled or C infection; or positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (HBsAg, anti-HBs, anti-HBc, or HBV DNA) or (HCV antibody or HCV RNA) infection at screening.
  • Known infection that is not well controlled.
  • Uncontrolled or significant cardiac disease, including myocardial infarction or uncontrolled/unstable angina within 6 months prior to C1D1, CHF ( Class II to IV), uncontrolled or significant cardiac arrhythmia, or uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
  • Investigator judgment of 1 or more of the following:

    • Mean resting corrected interval > 470 ms , obtained from triplicate ECGs performed at screening.
    • History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.
    • Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
  • History of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any , connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
  • .
  • corneal disease.
  • Known active tuberculosis infection

Prior/Concomitant Therapy

  • Any of the following prior anticancer therapies:

    • Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
    • TROP2-targeted therapy
    • Prior treatment with same ICC agent
  • Any concurrent anticancer treatment, with the exception of bisphosphonates, denosumab, for the treatment of bone .
  • Concurrent use of systemic hormonal replacement therapy (eg, estrogen). However, concurrent use of hormones for non-cancer related conditions (eg, insulin for diabetes) is acceptable.
  • Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.

Prior/Concurrent Clinical Study Experience

  • Previous treatment in the present study.
  • Participation in another clinical study with a study intervention or medicinal device administered in the last 4 weeks prior to first dosing, randomization into a prior Dato-DXd or T-DXd (trastuzumab deruxtecan) study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
  • Participants with a known to Dato-DXd, or any of the of the product (including, but not limited to, polysorbate 80).
  • Known history of severe hypersensitivity reactions to other monoclonal antibodies.

Other Exclusions

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
  • For women only, currently pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
732 participants (actual)

Study arms

  • Experimental
    Dato-DXd

    Arm 1: Dato-DXd

    Drug: Dato-DXd

  • Active comparator
    Investigators Choice of Chemotherapy (ICC)

    Arm 2: ICC Capecitabine Gemcitabine Eribulin mesylate Vinorelbine

    Drug: Capecitabine · Drug: Gemcitabine · Drug: Eribulin · Drug: Vinorelbine

Interventions

  • Experimental drug. Provided in 100mg vials. IV infusion.

    Also known as: Datopotamab deruxtecan (Dato-DXd, DS-1062a)

  • Tablet. Oral route of administration. Active comparator

  • IV Infusion. Active comparator

  • IV Infusion. Active comparator

    Also known as: Eribulin Mesylate

  • IV Infusion. Active comparator

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    PFS is defined as time from randomization until progression per RECIST 1.1, as assessed by BICR, or death due to any cause. The analysis will include all randomized participants as randomized regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy, or clinically progresses prior to RECIST 1.1.

    Time frame: On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months

  2. Overall Survival

    OS is defined as time from randomization until the date of death due to any cause. The comparison will include all randomized participants as randomized, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the hazard ratio of OS.

    Time frame: From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by the BICR/Investigator assessment, per RECIST 1.1.

    Time frame: From date of randomization until event. Assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months for BICR assessment and assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months for investigator assessment.

  2. Duration of Response (DoR) as Assessed by BICR Assessment

    Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR assessment or death due to any cause.

    Time frame: From date of first response until progression or death. Tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent. Assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months.

  3. Duration of Response (DoR) as Assessed by Investigator Assessment

    Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by Investigator assessment or death due to any cause.

    Time frame: From date of first response until progression or death. Tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months

  4. Progression-Free Survival by Investigator Assessment

    PFS by Investigator assessment will be defined as the time from the date of randomization until the date of PD per RECIST 1.1 (by Investigator assessment) or death (by any cause in the absence of progression), (ie, date of event or censoring - date of randomization + 1).

    Time frame: On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months

  5. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who have a confirmed CR or PR up to data cut-off date or who have SD for at least 11 weeks after randomization, per RECIST 1.1, as assessed BICR/per investigator assessment and derived from the raw tumor data.

    Time frame: Assessed up to data cut-off (17Jul2023) to a maximum of 21 months for BICR assessment and assessed up to data cut-off (24Jul2024) to a maximum of 33 months for investigator assessment.

  6. Time to First Subsequent Therapy (TFST)

    Time to first subsequent therapy is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.

    Time frame: From randomization to start of first subsequent anti-cancer therapy. Assessments occur at every visit after study treatment has been discontinued. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

  7. Time to Second Subsequent Therapy (TSST)

    Time to second subsequent therapy is defined as the time from randomization to until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: From randomization to start of second subsequent anti-cancer therapy. Assessments occur at every visit after study treatment has been discontinued. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

  8. Time From Randomization to Second Progression or Death (PFS2)

    Time to second progression of death will be defined as the time from the randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice.

    Time frame: From date of randomization to second progression or death. PFS2 assessments occur every 3 months after disease progression. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months

  9. Clinical Outcome Assessment- TTD in Pain

    Time to deterioration in pain as measured by the pain scale from EORTC QLQ-C30. Deterioration is defined as a 16.6 increase in score relative to baseline score

    Time frame: From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

  10. Clinical Outcome Assessment- TTD in Physical Functioning

    Time to deterioration in physical functioning as measured by the physical functioning scale from EORTC QLQ-C30. Deterioration is defined as a 13.3 decrease in score relative to baseline score.

    Time frame: From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

  11. Clinical Outcome Assessment- TTD in GHS

    Time to deterioration in global health status/QoL as measured by the global health status/QoL scale from EORTC QLQ-C30. Deterioration is defined as a 16.6 decrease in score relative to baseline score.

    Time frame: From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.

07

Results

Posted Feb 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Started365367
Completed00
Not completed365367
Withdrew: Reason unknown11
Withdrew: Ongoing in study at data cut-off date120131
Withdrew: Withdrawal by subject2529
Withdrew: Lost to follow-up52
Withdrew: Death214204

Outcome measures

PrimaryProgression-Free Survival

PFS is defined as time from randomization until progression per RECIST 1.1, as assessed by BICR, or death due to any cause. The analysis will include all randomized participants as randomized regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy, or clinically progresses prior to RECIST 1.1.

Time frame:
On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months
Reported as:
Median · Months
Progression-Free Survival
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Progression-Free Survival6.9 (5.7 to 7.4)4.9 (4.2 to 5.5)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.63 · 99% CI 0.49 to 0.80Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
PrimaryOverall Survival

OS is defined as time from randomization until the date of death due to any cause. The comparison will include all randomized participants as randomized, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the hazard ratio of OS.

Time frame:
From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Overall Survival
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Overall Survival18.6 (17.3 to 20.1)18.3 (17.3 to 20.5)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = 0.9445 (p-value adjusted for multiple testing) · Hazard ratio (hr): 1.01 · 95.97% CI 0.83 to 1.23Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryObjective Response Rate (ORR)

Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by the BICR/Investigator assessment, per RECIST 1.1.

Time frame:
From date of randomization until event. Assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months for BICR assessment and assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months for investigator assessment.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Confirmed response by BICR assessment based on IA1 data cut-off Raw Response Rate (%)36.44 (31.49 to 41.61)22.89 (18.69 to 27.53)
Confirmed response by investigator assessment based on FA data cut-off Raw Response Rate (%)36.71 (31.76 to 41.89)22.07 (17.93 to 26.67)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 1.95 · 95% CI 1.41 to 2.71An odds ratio \> 1 favours Dato-DXd
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.06 · 95% CI 1.49 to 2.87An odds ratio \> 1 favours Dato-DXd
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Difference in raw response rate: 13.55 · 95% CI 6.96 to 20.05A positive difference in response rates favours Dato-DXd. Calculated using the Miettinen-Nurminen method.
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Difference in raw response rate: 14.64 · 95% CI 8.08 to 21.11A positive difference in response rates favours Dato-DXd. Calculated using the Miettinen-Nurminen method.
SecondaryDuration of Response (DoR) as Assessed by BICR Assessment

Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR assessment or death due to any cause.

Time frame:
From date of first response until progression or death. Tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent. Assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months.
Reported as:
Median · Months
Duration of Response (DoR) as Assessed by BICR Assessment
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Duration of Response (DoR) as Assessed by BICR Assessment6.7 (5.6 to 9.8)5.7 (4.9 to 6.8)
SecondaryDuration of Response (DoR) as Assessed by Investigator Assessment

Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by Investigator assessment or death due to any cause.

Time frame:
From date of first response until progression or death. Tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months
Reported as:
Median · Months
Duration of Response (DoR) as Assessed by Investigator Assessment
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Duration of Response (DoR) as Assessed by Investigator Assessment7.2 (5.7 to 8.6)6.0 (4.7 to 7.7)
SecondaryProgression-Free Survival by Investigator Assessment

PFS by Investigator assessment will be defined as the time from the date of randomization until the date of PD per RECIST 1.1 (by Investigator assessment) or death (by any cause in the absence of progression), (ie, date of event or censoring - date of randomization + 1).

Time frame:
On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months
Reported as:
Median · Months
Progression-Free Survival by Investigator Assessment
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Progression-Free Survival by Investigator Assessment6.9 (5.9 to 7.2)4.5 (4.2 to 5.5)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.64 · 95% CI 0.55 to 0.76Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants who have a confirmed CR or PR up to data cut-off date or who have SD for at least 11 weeks after randomization, per RECIST 1.1, as assessed BICR/per investigator assessment and derived from the raw tumor data.

Time frame:
Assessed up to data cut-off (17Jul2023) to a maximum of 21 months for BICR assessment and assessed up to data cut-off (24Jul2024) to a maximum of 33 months for investigator assessment.
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Response by BICR assessment based on IA1 data cut-off Raw disease control rate (%)75.34 (70.59 to 79.68)63.76 (58.61 to 68.69)
Response by investigator assessment based on FA data cut-off Raw disease control rate (%)80.82 (76.40 to 84.73)66.76 (61.68 to 71.56)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Regression, Logistic · p = 0.0006 · Odds ratio (or): 1.75 · 95% CI 1.27 to 2.42An odds ratio \> 1 favours Dato-DXd
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.12 · 95% CI 1.51 to 3.00An odds ratio \> 1 favours Dato-DXd
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Difference in raw disease control rate: 11.58 · 95% CI 4.93 to 18.16A positive difference in response rates favours Dato-DXd. Calculated using the Miettinen-Nurminen method.
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Difference in raw disease control rate: 14.06 · 95% CI 7.74 to 20.33A positive difference in response rates favours Dato-DXd. Calculated using the Miettinen-Nurminen method.
SecondaryTime to First Subsequent Therapy (TFST)

Time to first subsequent therapy is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.

Time frame:
From randomization to start of first subsequent anti-cancer therapy. Assessments occur at every visit after study treatment has been discontinued. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST)
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Time to First Subsequent Therapy (TFST)8.0 (7.2 to 8.8)5.2 (4.6 to 5.8)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Hazard ratio (hr): 0.58 · 95% CI 0.50 to 0.68Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryTime to Second Subsequent Therapy (TSST)

Time to second subsequent therapy is defined as the time from randomization to until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

Time frame:
From randomization to start of second subsequent anti-cancer therapy. Assessments occur at every visit after study treatment has been discontinued. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Time to Second Subsequent Therapy (TSST)
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Time to Second Subsequent Therapy (TSST)13.7 (12.4 to 15.0)12.3 (10.8 to 13.7)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Hazard ratio (hr): 0.83 · 95% CI 0.70 to 0.98Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryTime From Randomization to Second Progression or Death (PFS2)

Time to second progression of death will be defined as the time from the randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice.

Time frame:
From date of randomization to second progression or death. PFS2 assessments occur every 3 months after disease progression. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months
Reported as:
Median · Months
Time From Randomization to Second Progression or Death (PFS2)
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Time From Randomization to Second Progression or Death (PFS2)11.7 (10.8 to 13.1)10.4 (9.6 to 11.5)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Hazard ratio (hr): 0.76 · 95% CI 0.63 to 0.93Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryClinical Outcome Assessment- TTD in Pain

Time to deterioration in pain as measured by the pain scale from EORTC QLQ-C30. Deterioration is defined as a 16.6 increase in score relative to baseline score

Time frame:
From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Clinical Outcome Assessment- TTD in Pain
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Clinical Outcome Assessment- TTD in Pain3.5 (2.8 to 5.0)2.8 (2.1 to 3.4)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = 0.1519 · Hazard ratio (hr): 0.84 · 95% CI 0.67 to 1.06Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryClinical Outcome Assessment- TTD in Physical Functioning

Time to deterioration in physical functioning as measured by the physical functioning scale from EORTC QLQ-C30. Deterioration is defined as a 13.3 decrease in score relative to baseline score.

Time frame:
From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Clinical Outcome Assessment- TTD in Physical Functioning
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Clinical Outcome Assessment- TTD in Physical Functioning5.6 (3.5 to 9.7)3.5 (2.2 to 4.9)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = 0.0596 · Hazard ratio (hr): 0.79 · 95% CI 0.62 to 1.01Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.
SecondaryClinical Outcome Assessment- TTD in GHS

Time to deterioration in global health status/QoL as measured by the global health status/QoL scale from EORTC QLQ-C30. Deterioration is defined as a 16.6 decrease in score relative to baseline score.

Time frame:
From date of randomization to 18 weeks post-progression. Assessments occur every 3 weeks then every 6 weeks until 18 weeks post-progression and at end of treatment visit. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Reported as:
Median · Months
Clinical Outcome Assessment- TTD in GHS
MonthsDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Clinical Outcome Assessment- TTD in GHS3.4 (2.1 to 5.0)2.1 (1.5 to 2.9)
Statistical analysis
  • Dato-DXd vs Investigator's Choice of Chemotherapy (ICC) · Log Rank · p = 0.1155 · Hazard ratio (hr): 0.83 · 95% CI 0.67 to 1.04Stratified Cox Proportional Hazards model. A hazard ratio \< 1 favours Dato-DXd.

Adverse events

Collected over Adverse Event data was collected from time of signature of informed consent until the follow-up period is completed (35 days after the last dose of study treatment) (maximum duration of approximately 28 months). All-Cause Mortality was assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dato-DXd223/365 (61.1%)62/360 (17.2%)348/360 (96.7%)
Investigator's Choice of Chemotherapy (ICC)213/367 (58%)67/351 (19.1%)329/351 (93.7%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventDato-DXdInvestigator's Choice of Chemotherapy (ICC)
Febrile neutropeniaBlood and lymphatic system disorders0/3605/351
Urinary tract infectionInfections and infestations5/3603/351
PneumoniaInfections and infestations2/3604/351
Femur fractureInjury, poisoning and procedural complications1/3604/351
Covid-19Infections and infestations4/3603/351
Pleural effusionRespiratory, thoracic and mediastinal disorders2/3603/351
PneumonitisRespiratory, thoracic and mediastinal disorders3/3600/351
SepsisInfections and infestations3/3601/351
UrosepsisInfections and infestations3/3600/351
Cardiac failureCardiac disorders0/3602/351
Most frequent other events
Showing 10 of 46
Most frequent other events
EventDato-DXdInvestigator's Choice of Chemotherapy (ICC)
NauseaGastrointestinal disorders204/36095/351
StomatitisGastrointestinal disorders188/36049/351
AlopeciaSkin and subcutaneous tissue disorders136/36080/351
ConstipationGastrointestinal disorders126/36060/351
FatigueGeneral disorders102/36071/351
Dry eyeEye disorders97/36046/351
NeutropeniaBlood and lymphatic system disorders21/36091/351
AnaemiaBlood and lymphatic system disorders62/36086/351
VomitingGastrointestinal disorders86/36041/351
Neutrophil count decreasedInvestigations25/36075/351

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dato-DXdInvestigator's Choice of Chemotherapy (ICC)Total
Median56.0 (29 to 86)54.0 (28 to 86)55.0 (28 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Dato-DXdInvestigator's Choice of Chemotherapy (ICC)Total
Female360363723
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dato-DXdInvestigator's Choice of Chemotherapy (ICC)Total
Hispanic or Latino404383
Not Hispanic or Latino322318640
Unknown or Not Reported369
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dato-DXdInvestigator's Choice of Chemotherapy (ICC)Total
Black or African American4711
Native Hawaiian or other Pacific Islander000
American Indian or Alaska Native000
Asian146152298
White180170350
Other369
Not reported323264
08

Study locations

167 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Palo Alto, California 94305-5826, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Jacksonville, Florida 32207, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Cleveland, Ohio 44119, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Richmond, Virginia 23219, United States
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1280AEB, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, 2123, Argentina
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Itajaí, 88301-220, Brazil
  • Research Site
    Jaú, 17210-070, Brazil
  • Research Site
    Porto Alegre, 90035903, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    São Paulo, 01236-030, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 1323001, Brazil
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100071, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Jinan, 250001, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Shanghai, 200000, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Bezannes, 51430, France
  • Research Site
    Bordeaux, 33030, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Plérin, 22190, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    Leipzig, 4103, Germany
  • Research Site
    München, 80637, Germany
  • Research Site
    Ravensburg, 88212, Germany
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Szekszárd, 7100, Hungary
  • Research Site
    Szolnok, 5000, Hungary
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Howrah, 711103, India
  • Research Site
    Hyderabad, 500084, India
  • Research Site
    Jaipur, 302022, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Nashik, 422009, India
  • Research Site
    Surat, 395002, India
  • Research Site
    Visakhapatnam, 530017, India
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Florence, 50139, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Prato, 59100, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Fukuoka, 811-1395, Japan
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Hiroshima, 730-8518, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kagoshima, 892-0833, Japan
  • Research Site
    Kashiwa, 227-8577, Japan

Showing the first 100 of 167 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martinez Janez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025 Jan 20;43(3):285-296. doi: 10.1200/JCO.24.00920. Epub 2024 Sep 12. PubMed 39265124 ↗
  • Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Janez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30. PubMed 37387213 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2024, 33 months.

Results were first posted in Feb 2026, 1 year 6 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Nov 3, 2021
StartActual
Oct 18, 2021
Primary completionActual
Jul 24, 2024
CompletionEst.
Dec 31, 2026
Results first posted
Feb 4, 2026
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05104866
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Oct 18, 2021
Primary completion
Jul 24, 2024
Completion
Dec 31, 2026 (estimated)
Results posted
Feb 4, 2026
Last update
Aug 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion